

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement appears for information purposes only and is not intended to and does not constitute, or form part of, any offer to purchase or subscribe for or an invitation to purchase or subscribe for any securities of the Offeror or the Company or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of the Company in any jurisdiction in contravention of applicable law.



Meditech Global Group Limited

*(Incorporated in the British Virgin Islands
with limited liability)*

GOLDEN MEDITECH HOLDINGS LIMITED

金衛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00801)

JOINT ANNOUNCEMENT

**ON (1) PROPOSAL FOR THE PRIVATISATION OF
GOLDEN MEDITECH HOLDINGS LIMITED BY THE OFFEROR
BY WAY OF A SCHEME OF ARRANGEMENT
(UNDER SECTION 86 OF THE COMPANIES LAW)**

(2) PROPOSED WITHDRAWAL OF LISTING

AND

(3) SPECIAL DEAL RELATING TO THE UNDERTAKING

CLARIFICATION ANNOUNCEMENT

**ON FORMS OF PROXY
FOR USE AT THE COURT MEETING AND THE GENERAL MEETING
TO BE HELD ON WEDNESDAY, 16 SEPTEMBER 2020
(OR ANY ADJOURNMENT THEREOF)**

Financial Adviser to the Offeror

AMASSE CAPITAL
寶 積 資 本

Independent Financial Adviser to the Company



SOMERLEY CAPITAL LIMITED

INTRODUCTION

Reference is made to the composite scheme document dated 21 August 2020 (the “**Scheme Document**”) issued jointly by Golden Meditech Holdings Limited (the “**Company**”) and Meditech Global Group Limited (the “**Offeror**”) in relation to, among other things, the proposed privatisation of the Company by way of a scheme of arrangement (the “**Scheme**”). Capitalised terms used herein shall have the same meanings as those defined in the Scheme Document unless the context requires otherwise.

Form of Proxy

On 21 August 2020, the following forms of proxy were despatched to the Shareholders together with the Scheme Document:

- (1) the form of proxy for use at the Court Meeting (the “**Court Meeting Proxy Form**”); and
- (2) the form of proxy for use at the General Meeting (the “**General Meeting Proxy Form**”).

It was stated in the Scheme Document that the Court Meeting Proxy Form would be a pink form of proxy and the General Meeting Proxy Form would be a white form of proxy. Therefore, the Court Meeting Proxy Form should have been printed on pink paper and the General Meeting Proxy Form should have been printed on white paper. However, due to a printing error, both the Court Meeting Proxy Form and the General Meeting Proxy Form despatched to the Shareholders on 21 August 2020 were printed on white paper.

The Company wishes to clarify that save for the colour of the paper, the contents of the Court Meeting Proxy Form despatched to the Shareholders on 21 August 2020 are correct. For the avoidance of doubt, if a Court Meeting Proxy Form (that is printed on white paper) is used, the appointment of a proxy in respect of the Court Meeting will not be invalid merely due to the colour of the form of proxy.

Save as disclosed above, all information in and contents as set out in the Scheme Document, the Court Meeting Proxy Form and the General Meeting Proxy Form remain unchanged. The Court Meeting Proxy Form, the General Meeting Proxy Form, and the notices of the Court Meeting and the General Meeting, despatched together with the Scheme Document, remain valid.

General

Shareholders who have questions about which forms of proxy are to be completed, signed and returned may contact the Company’s share registrar, Computershare Hong Kong Investor Services Limited at +852 2862 8555 between 9:00 a.m. and 6:00 p.m. on Monday to Friday, excluding public holidays and any day on which a tropical cyclone warning no. 8 or above is hoisted or on which a black rainstorm signal is hoisted.

This clarification announcement is supplemental to and should be read in conjunction with the Scheme Document and the notice of Court Meeting.

WARNING: Shareholders and potential investors should be aware that the implementation of the Proposal is subject to the Conditions being fulfilled or waived, as applicable, and thus the Proposal may or may not be implemented and the Scheme may or may not become effective. Shareholders and potential investors should therefore exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor or other professional advisers.

By order of the board of
Meditech Global Group Limited
KAM Yuen
Sole Director

By order of the board of
Golden Meditech Holdings Limited
Feng Wen
Chairman

Hong Kong, 24 August 2020

As at the date of this joint announcement, the Board comprises five Directors. The executive Directors are Mr. Feng Wen (Chairman) and Mr. Leong Kim Chuan (Chief Executive); and the independent non-executive Directors are Mr. Gao Yue, Mr. Poon Tsz Hang and Mr. Daniel Foa.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Offeror or any of the Offeror Concert Parties) and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Offeror or any of the Offeror Concert Parties) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.

As at the date of this joint announcement, (i) the sole director of the Offeror is Mr. Kam; (ii) the sole director of Bio Garden Inc. is Mr. Kam; (iii) the sole director of China In Shine Investment Limited is Ms. Fung Chit; (iv) the sole director of Asia Pacific MedTech (BVI) Limited is Ms. Gu Nana; and (v) the sole director of Famous Sino Limited is Mr. Wu Guangze.

Mr. Kam (in his capacity as the sole director of the Offeror) accepts full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Group) and confirm, having made all reasonable inquiries, that to the best of his knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.

Mr. Kam (in his capacity as the sole director of Bio Garden Inc.), Ms. Fung Chit (in her capacity as the sole director of China In Shine Investment Limited), Ms. Gu Nana (in her capacity as the sole director of Asia Pacific MedTech (BVI) Limited) and Mr. Wu Guangze (in his capacity as the sole director of Famous Sino Limited) jointly and severally accepts full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Group) and confirm, having made all reasonable inquiries, that to the best of her/his knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.